Moreover, pioglitazone is a potent insulin sensitiser, retards onset of type 2 diabetes by protecting beta cell function, and reduces CVD, which is a frequent comorbidity in individuals with type 2 diabetes and/or NAFLD [14]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.